Stowasser Michael, Gordon Richard D, Gunasekera Thanuja G, Cowley Diane C, Ward Gregory, Archibald Colin, Smithers B Mark
Hypertension Unit, University of Queensland Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia.
J Hypertens. 2003 Nov;21(11):2149-57. doi: 10.1097/00004872-200311000-00025.
Wide testing of the aldosterone : renin ratio among hypertensive individuals has revealed primary aldosteronism to be common, with most patients normokalaemic. Some investigators, however, have reported aldosterone-producing adenoma to be rare among patients so detected.
To test the hypothesis that differences among reported studies in the rate of detection of aldosterone-producing adenoma (as opposed to bilateral adrenal hyperplasia) reflect differences in the procedures used for diagnosis of primary aldosteronism, and the methods used to identify aldosterone-producing adenomas.
In the newly established Princess Alexandra Hospital Hypertension Unit (PAHHU), we used procedures developed by Greenslopes Hospital Hypertension Unit (which reports that more than 30% of patients with primary aldosteronism have aldosterone-producing adenomas) to diagnose primary aldosteronism and determine the subtype. All patients with an increased aldosterone : renin ratio (measured after correction for hypokalaemia and while the patient was not receiving interfering medications) underwent fludrocortisone suppression testing to confirm or exclude primary aldosteronism; if they were positive, they underwent genetic testing to exclude glucocorticoid-remediable aldosteronism before adrenal venous sampling was used to differentiate lateralizing from bilateral primary aldosteronism.
This approach allowed PAHHU to diagnose, within 2 years, 54 patients [only seven (13%) hypokalaemic] with primary aldosteronism. All tested negative for glucocorticoid-remediable aldosteronism. Aldosterone production was lateralized to one adrenal in 15 patients (31%; only six hypokalaemic) and was bilateral in 34 (69%; all normokalaemic) of 49 patients who underwent adrenal venous sampling. Among patients with lateralizing adrenal hyperplasia, computed tomography revealed an ipsilateral mass in only six and a contralateral lesion in one. Fourteen patients underwent unilateral adrenalectomy, which cured the hypertension in seven and improved it in the remainder. In patients with bilateral primary aldosteronism, hypertension responded to spironolactone (12.5-50 mg/day) or amiloride (2.5-10 mg/day).
When performed with careful regard to confounding factors, measurement of the aldosterone : renin ratio in all hypertensive individuals, followed by fludrocortisone suppression testing to confirm or exclude primary aldosteronism and adrenal venous sampling to determine the subtype, can result in the detection of significant numbers of patients with specifically treatable or potentially curable hypertension.
对高血压患者进行醛固酮:肾素比值的广泛检测发现原发性醛固酮增多症很常见,大多数患者血钾正常。然而,一些研究者报告称,在检测出的患者中,醛固酮瘤很少见。
检验以下假设,即已发表研究中醛固酮瘤(相对于双侧肾上腺增生)检出率的差异反映了原发性醛固酮增多症诊断程序以及醛固酮瘤识别方法的差异。
在新成立的亚历山德拉公主医院高血压科(PAHHU),我们采用了格林斯洛普斯医院高血压科开发的程序(该科室报告称,超过30%的原发性醛固酮增多症患者患有醛固酮瘤)来诊断原发性醛固酮增多症并确定其亚型。所有醛固酮:肾素比值升高的患者(在纠正低钾血症后且未服用干扰药物时测量)均接受氟氢可的松抑制试验以确诊或排除原发性醛固酮增多症;如果结果为阳性,则在进行肾上腺静脉采血以区分单侧与双侧原发性醛固酮增多症之前,先进行基因检测以排除糖皮质激素可治性醛固酮增多症。
通过这种方法,PAHHU在2年内诊断出54例原发性醛固酮增多症患者[仅7例(13%)低钾血症]。所有患者糖皮质激素可治性醛固酮增多症检测均为阴性。在接受肾上腺静脉采血的49例患者中,15例(31%;仅6例低钾血症)醛固酮分泌单侧化至一侧肾上腺,34例(69%;均血钾正常)为双侧。在单侧肾上腺增生的患者中,计算机断层扫描仅发现6例同侧有肿块,1例对侧有病变。14例患者接受了单侧肾上腺切除术,其中7例患者高血压得到治愈,其余患者病情有所改善。在双侧原发性醛固酮增多症患者中,高血压对螺内酯(12.5 - 50毫克/天)或氨氯吡咪(2.5 - 10毫克/天)有反应。
在充分考虑混杂因素的情况下,对所有高血压患者测量醛固酮:肾素比值,随后进行氟氢可的松抑制试验以确诊或排除原发性醛固酮增多症,并进行肾上腺静脉采血以确定亚型,能够检测出大量患有特定可治疗或潜在可治愈高血压的患者。